RMC-6291

• Description:

  RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models .

• Stability:

  ≥ 2 years

• Purity:

  >98% (HPLC)

• Weight:

  1012.26

• Molecular Formula:

  C55H78FN9O8

• Notes:

  Research use only, not for human use.

• Receptor:

  Kras

• CAS Number:

  2641998-63-0